Advertisement
Advertisement

CLYM

CLYM logo

Climb Bio Inc.

2.05
USD
-0.29
-12.39%
Dec 18, 15:17 UTC -5
Open

Climb Bio Inc. Profile

About

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Info & Links

CEO

Andrew Levin

Headquarters

2801 Centerville Road 1st Floor
Wilmington, DE 19808, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.eliemtx.com

Auditor

PricewaterhouseCoopers LLP

Share holders

15

Employees

11

Climb Bio Inc. Statistics

Valuation Measures

Market Capitalization2

137.80M

Enterprise Value

-8.37M

Enterprise Value/EBITDA(ttm)

0.11

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.80

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-42.21%

Return on Invested Capital(ttm)

-33.74%

Return on Assets(ttm)

-41.39%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-76.81M

Net Income Available to Common(ttm)

-69.12M

Diluted EPS(ttm)

-2.13

Share Statistics

Beta (5Y Monthly)

-0.40

52-Week Change

-21.15%

S&P 500 52-Week Change

25.73%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

67.22M

Dividend Yield

0.00%

Float4

65.07M

% Held by Insiders

3.20%

% Held by Institutions

69.76%

Balance Sheet

Total Cash(mrq)

193.35M

Total Cash Per Share(mrq)

2.88

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

57.73%

Quick Ratio(mrq)

57.73%

Book Value Per Share(mrq)

3.25

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.15

Free Cash Flow(ytd)

-10.04M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement